These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

773 related items for PubMed ID: 29516535

  • 21. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
    Kuwano A, Yada M, Nagasawa S, Tanaka K, Morita Y, Masumoto A, Motomura K.
    J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
    [Abstract] [Full Text] [Related]

  • 22. Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan.
    Chang CW, Hsu WF, Tseng KC, Chen CY, Cheng PN, Hung CH, Lo CC, Bair MJ, Chen CH, Lee PL, Lin CY, Kuo HT, Chen CT, Yang CC, Huang JF, Tai CM, Hu JT, Lin CL, Su WW, Tsai WL, Huang YH, Cheng CY, Lin CL, Wang CC, Yang SS, Mo LR, Chen GY, Chang CC, Wang SJ, Huang CS, Hsieh TY, Lin CW, Lee TH, Chong LW, Huang CW, Chang SN, Tsai MC, Hsu SJ, Kao JH, Liu CJ, Liu CH, Lin HC, Tsai PC, Yeh ML, Huang CF, Dai CY, Chuang WL, Yu ML, Peng CY.
    Dig Dis Sci; 2024 Sep; 69(9):3501-3512. PubMed ID: 38965159
    [Abstract] [Full Text] [Related]

  • 23. DAA treatment for HCV reduce risk of hepatocellular carcinoma: a 10-years follow-up study based on Chinese patients with hepatitis C.
    Zhu X, Jia L, Yue M, Zhang A, Xia X, Yu R, Chen H, Huang P.
    Sci Rep; 2024 Oct 10; 14(1):23760. PubMed ID: 39390065
    [Abstract] [Full Text] [Related]

  • 24. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
    Toyoda H, Kumada T, Tada T, Mizuno K, Sone Y, Akita T, Tanaka J, Johnson PJ.
    Liver Int; 2019 Mar 10; 39(3):448-454. PubMed ID: 30312003
    [Abstract] [Full Text] [Related]

  • 25. No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.
    Mun EJ, Green P, Berry K, Ioannou GN.
    Eur J Gastroenterol Hepatol; 2019 Jan 10; 31(1):47-52. PubMed ID: 30142097
    [Abstract] [Full Text] [Related]

  • 26. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
    Kobayashi M, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2017 Mar 10; 89(3):476-483. PubMed ID: 27531586
    [Abstract] [Full Text] [Related]

  • 27. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
    Hamoir C, Horsmans Y, Stärkel P, Dahlqvist G, Negrin Dastis S, Lanthier N.
    Acta Gastroenterol Belg; 2021 Mar 10; 84(1):25-32. PubMed ID: 33639690
    [Abstract] [Full Text] [Related]

  • 28. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
    McDonald SA, Pollock KG, Barclay ST, Goldberg DJ, Bathgate A, Bramley P, Dillon JF, Fraser A, Innes HA, Kennedy N, Morris J, Went A, Hayes PC, Hutchinson SJ.
    J Viral Hepat; 2020 Mar 10; 27(3):270-280. PubMed ID: 31696575
    [Abstract] [Full Text] [Related]

  • 29. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
    Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND.
    Gastroenterology; 2019 May 10; 156(6):1683-1692.e1. PubMed ID: 30660729
    [Abstract] [Full Text] [Related]

  • 30. Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
    Sangiovanni A, Alimenti E, Gattai R, Filomia R, Parente E, Valenti L, Marzi L, Pellegatta G, Borgia G, Gambato M, Terreni N, Serio I, Belli L, Oliveri F, Maimone S, Brunacci M, D'Ambrosio R, Forzenigo LV, Russo FP, Rumi M, Barone M, Fracanzani AL, Raimondo G, Giannini EG, Brunetto MR, Villa E, Biganzoli E, Colombo M, Lampertico P.
    J Hepatol; 2020 Sep 10; 73(3):593-602. PubMed ID: 32243959
    [Abstract] [Full Text] [Related]

  • 31. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
    Kozbial K, Moser S, Al-Zoairy R, Schwarzer R, Datz C, Stauber R, Laferl H, Strasser M, Beinhardt S, Stättermayer AF, Gschwantler M, Zoller H, Maieron A, Graziadei I, Trauner M, Steindl-Munda P, Hofer H, Ferenci P.
    Liver Int; 2018 Jun 10; 38(6):1028-1035. PubMed ID: 29136329
    [Abstract] [Full Text] [Related]

  • 32. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C.
    Ogawa E, Chien N, Kam L, Yeo YH, Ji F, Huang DQ, Cheung R, Nguyen MH.
    JAMA Intern Med; 2023 Feb 01; 183(2):97-105. PubMed ID: 36508196
    [Abstract] [Full Text] [Related]

  • 33. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G, Ansaldi F, Andorno E, Ravetti GL, Ferro C, De Iaco F, Icardi G, Valente U.
    Hepatogastroenterology; 2002 Feb 01; 49(48):1636-8. PubMed ID: 12397752
    [Abstract] [Full Text] [Related]

  • 34. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
    Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio R, Morio K, Kan H, Fujino H, Kobayashi T, Masaki K, Ono A, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Hayes CN, Miki D, Ochi H, Chayama K.
    PLoS One; 2017 Feb 01; 12(8):e0182710. PubMed ID: 28797106
    [Abstract] [Full Text] [Related]

  • 35. De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era.
    Kwong AJ, Kim WR, Flemming JA.
    Hepatology; 2018 Oct 01; 68(4):1288-1297. PubMed ID: 29672886
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
    Degasperi E, Galmozzi E, Pelusi S, D'Ambrosio R, Soffredini R, Borghi M, Perbellini R, Facchetti F, Iavarone M, Sangiovanni A, Valenti L, Lampertico P.
    Hepatology; 2020 Dec 01; 72(6):1912-1923. PubMed ID: 32762045
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.